Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: implications for anticancer drug screening programs

R M Phillips, J Pearce, P M Loadman, M C Bibby, Patricia A Cooper, D J Swaine, J A Double

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The National Cancer Institute uses the hollow fiber assay as part of its screening program for anticancer drug discovery. Angiogenesis to hollow fibers implanted s.c. has not been reported, thereby raising concerns about the efficiency of drug delivery and its subsequent effects on chemosensitivity. By extending postimplantation times beyond the 6-day period presently used, extensive vascular networks develop, resulting in both increased delivery and chemosensitivity to doxorubicin. This study suggests that present protocols used to evaluate compounds may produce false negative results, and additional studies to determine the predictive value of the assay are required.

LanguageEnglish
Pages5263-5266
Number of pages4
JournalCancer Research
Volume58
Issue number23
Publication statusPublished - 1 Dec 1998
Externally publishedYes

Fingerprint

Preclinical Drug Evaluations
National Cancer Institute (U.S.)
Drug Discovery
Doxorubicin
Blood Vessels
Pharmaceutical Preparations
Neoplasms

Cite this

Phillips, R. M., Pearce, J., Loadman, P. M., Bibby, M. C., Cooper, P. A., Swaine, D. J., & Double, J. A. (1998). Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: implications for anticancer drug screening programs. Cancer Research, 58(23), 5263-5266.
Phillips, R M ; Pearce, J ; Loadman, P M ; Bibby, M C ; Cooper, Patricia A ; Swaine, D J ; Double, J A. / Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells : implications for anticancer drug screening programs. In: Cancer Research. 1998 ; Vol. 58, No. 23. pp. 5263-5266.
@article{29b6635beef647489de82f5753f54a8a,
title = "Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: implications for anticancer drug screening programs",
abstract = "The National Cancer Institute uses the hollow fiber assay as part of its screening program for anticancer drug discovery. Angiogenesis to hollow fibers implanted s.c. has not been reported, thereby raising concerns about the efficiency of drug delivery and its subsequent effects on chemosensitivity. By extending postimplantation times beyond the 6-day period presently used, extensive vascular networks develop, resulting in both increased delivery and chemosensitivity to doxorubicin. This study suggests that present protocols used to evaluate compounds may produce false negative results, and additional studies to determine the predictive value of the assay are required.",
keywords = "Adenocarcinoma/blood supply, Animals, Antibiotics, Antineoplastic/pharmacokinetics, Antineoplastic Agents/pharmacokinetics, Colonic Neoplasms/blood supply, Disease Models, Animal, Doxorubicin/pharmacokinetics, Drug Screening Assays, Antitumor/methods, Injections, Subcutaneous, Mice, Mice, Nude, Neoplasm Transplantation, Neovascularization, Pathologic/metabolism, Tumor Cells, Cultured",
author = "Phillips, {R M} and J Pearce and Loadman, {P M} and Bibby, {M C} and Cooper, {Patricia A} and Swaine, {D J} and Double, {J A}",
year = "1998",
month = "12",
day = "1",
language = "English",
volume = "58",
pages = "5263--5266",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

Phillips, RM, Pearce, J, Loadman, PM, Bibby, MC, Cooper, PA, Swaine, DJ & Double, JA 1998, 'Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: implications for anticancer drug screening programs', Cancer Research, vol. 58, no. 23, pp. 5263-5266.

Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells : implications for anticancer drug screening programs. / Phillips, R M; Pearce, J; Loadman, P M; Bibby, M C; Cooper, Patricia A; Swaine, D J; Double, J A.

In: Cancer Research, Vol. 58, No. 23, 01.12.1998, p. 5263-5266.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells

T2 - Journal of Cancer Research

AU - Phillips, R M

AU - Pearce, J

AU - Loadman, P M

AU - Bibby, M C

AU - Cooper, Patricia A

AU - Swaine, D J

AU - Double, J A

PY - 1998/12/1

Y1 - 1998/12/1

N2 - The National Cancer Institute uses the hollow fiber assay as part of its screening program for anticancer drug discovery. Angiogenesis to hollow fibers implanted s.c. has not been reported, thereby raising concerns about the efficiency of drug delivery and its subsequent effects on chemosensitivity. By extending postimplantation times beyond the 6-day period presently used, extensive vascular networks develop, resulting in both increased delivery and chemosensitivity to doxorubicin. This study suggests that present protocols used to evaluate compounds may produce false negative results, and additional studies to determine the predictive value of the assay are required.

AB - The National Cancer Institute uses the hollow fiber assay as part of its screening program for anticancer drug discovery. Angiogenesis to hollow fibers implanted s.c. has not been reported, thereby raising concerns about the efficiency of drug delivery and its subsequent effects on chemosensitivity. By extending postimplantation times beyond the 6-day period presently used, extensive vascular networks develop, resulting in both increased delivery and chemosensitivity to doxorubicin. This study suggests that present protocols used to evaluate compounds may produce false negative results, and additional studies to determine the predictive value of the assay are required.

KW - Adenocarcinoma/blood supply

KW - Animals

KW - Antibiotics, Antineoplastic/pharmacokinetics

KW - Antineoplastic Agents/pharmacokinetics

KW - Colonic Neoplasms/blood supply

KW - Disease Models, Animal

KW - Doxorubicin/pharmacokinetics

KW - Drug Screening Assays, Antitumor/methods

KW - Injections, Subcutaneous

KW - Mice

KW - Mice, Nude

KW - Neoplasm Transplantation

KW - Neovascularization, Pathologic/metabolism

KW - Tumor Cells, Cultured

M3 - Article

VL - 58

SP - 5263

EP - 5266

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 23

ER -